Can Capmatinib be used with chemotherapy drugs?

Capmatinib (Capmatinib) is a highly selective METtyrosine kinase inhibitor, mainly used to treat patients with MET exon 14 skipping mutations in advanced non-small cell lung cancer (NSCLC). As a targeted drug, capmatinib inhibits the growth and spread of tumor cells by blocking the MET signaling pathway. In clinical practice, some patients may have received or are receiving chemotherapy, so whether capmatinib can be used in combination with chemotherapy drugs is often concerned.

From a mechanistic point of view, there is no absolute contraindication for the combination of capmatinib and chemotherapy drugs, but this type of combination therapy has not yet been widely incorporated into routine treatment plans. The current registered clinical trials of capmatinib (such as GEOMETRY mono-1) are mainly aimed at evaluating the efficacy and safety of monotherapy, and do not involve a large amount of data on combined use with conventional chemotherapy drugs (such as pemetrexed, cisplatin, paclitaxel, etc.). Therefore, although synergistic effects may exist in theory, relevant evidence of efficacy and safety is insufficient.

It should be noted that both capmatinib and chemotherapy drugs may cause certain toxicity to liver function, blood system and gastrointestinal tract. If used together, the risk of additive side effects may increase, such as nausea, vomiting, fatigue, neutropenia, and elevated liver enzymes. Therefore, if clinicians consider using a combination regimen, they must closely monitor the patient's liver function, blood routine, and overall tolerance, and adjust the dose or interval of treatment cycles if necessary to ensure safety.

In summary, although capmatinib can be used in combination with chemotherapy agents in certain circumstances, this decision should be made by the oncologist based on individualized circumstances, tolerability, mutational status, and previous treatment regimens. It is still recommended that capmatinib be the preferred choice for monotherapy, especially in patients with positive MET mutations. If combined chemotherapy is considered, it is recommended to give priority to clinical trials or expert guidance.

Reference materials:https://www.drugs.com/